Drug Development

Oct 01, 2007
Pharmaceutical Technology Europe
The authors consider the advantages of using rapidly dissolving films to accurately and effectively deliver pharmaceutical ingredients, with an emphasis on the importance of controlling moisture content and drug loading during formulation development.
Sep 01, 2007
Pharmaceutical Technology Europe
A new Raman spectroscopic method to detect magnesium stearate in powder blends and tablets is described. High-volume pharmaceutical manufacturing requires the use of lubricants to facilitate tablet ejection from compressing machines. However, lubricants may also bring a number of undesired problems that have been widely documented in pharmaceutical scientific literature. New analytical methods are needed to understand lubrication and provide process knowledge in support of FDA's process analytical technology initiative. The detection of magnesium stearate in lactose, mannitol, corn starch and other commercially important excipients is reported. The Raman spectroscopic method has a detection limit of about 0.1% (w/w) based on the 2848 cm-1 band that corresponds to the symmetric stretch of the methylene group in magnesium stearate.
Sep 01, 2007
Pharmaceutical Technology Europe
This article investigates how the industry can test inhalers in a way that is most representative of typical use.
Sep 01, 2007
Pharmaceutical Technology Europe
A new economical method for producing fast-melting lamina-like dosage forms.
Jun 01, 2007
Pharmaceutical Technology Europe
Predicting the flow characteristics of powders during manufacture is especially important for the pharmaceutical engineer. Getting the powder flow wrong can be highly disruptive to plant performance and productivity, particularly where equipment has to be taken off-line and stripped down for cleaning out blockages. The flow behaviour of the individual ingredients may be well known, but as these are blended and reacted their flow properties can change.
May 01, 2007
Pharmaceutical Technology Europe
Green chemistry involves redesigning processes so that more of the raw material ends up in the product, rather than as waste...
May 01, 2007
Pharmaceutical Technology Europe
One of the major concerns with introducing PAT, however, is that the bias towards process engineering may not ultimately lead to complete control of product quality.
May 01, 2007
Pharmaceutical Technology Europe
There is a tremendous need to enhance delivery of potential therapeutics to the brain for treatment of central nervous system (CNS) disorders. The blood brain barrier (BBB) restricts and controls the exchange of compounds between the CNS and the blood, which requires discovery of new modalities allowing for effective drug delivery to the CNS. Polymer nanotechnology has now become one of the most attractive areas of pharmaceutical research. This review focuses on the current progress in polymeric nanoparticles, where the specific arrangement of the polymeric matter at the nanoscale is utilized to design drug delivery systems that provide safe and efficient transport of CNS drugs across the BBB.
Apr 01, 2007
Pharmaceutical Technology Europe
When a dosage form or an API is introduced to the gastrointestinal tract, or dissolution media mimicking it, a transformation from a metastable to a more stable form with lower solubility and bioavailability is possible.
Apr 01, 2007
Pharmaceutical Technology Europe
There have been significant advances, especially in understanding the role of carrier properties on the aerosol performance of the API.
native1_300x100
lorem ipsum